Aspira Women's Health Inc.

DB:CUL Stock Report

Market Cap: €12.3m

Aspira Women's Health Management

Management criteria checks 0/4

Aspira Women's Health's CEO is Nicole Sandford, appointed in Mar 2022, has a tenure of 2.58 years. total yearly compensation is $1.04M, comprised of 48.3% salary and 51.7% bonuses, including company stock and options. directly owns 0.52% of the company’s shares, worth €64.11K. The average tenure of the management team and the board of directors is 0.8 years and 1.4 years respectively.

Key information

Nicole Sandford

Chief executive officer

US$1.0m

Total compensation

CEO salary percentage48.3%
CEO tenure2.6yrs
CEO ownership0.5%
Management average tenureless than a year
Board average tenure1.4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Nicole Sandford's remuneration changed compared to Aspira Women's Health's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-US$16m

Mar 31 2024n/an/a

-US$15m

Dec 31 2023US$1mUS$500k

-US$17m

Sep 30 2023n/an/a

-US$18m

Jun 30 2023n/an/a

-US$21m

Mar 31 2023n/an/a

-US$27m

Dec 31 2022US$588kUS$417k

-US$30m

Sep 30 2022n/an/a

-US$34m

Jun 30 2022n/an/a

-US$36m

Mar 31 2022n/an/a

-US$35m

Dec 31 2021US$147kn/a

-US$32m

Compensation vs Market: Nicole's total compensation ($USD1.04M) is above average for companies of similar size in the German market ($USD501.82K).

Compensation vs Earnings: Nicole's compensation has increased whilst the company is unprofitable.

CEO

Nicole Sandford (54 yo)

2.6yrs

Tenure

US$1,035,590

Compensation

Ms. Nicole Sandford, C. P.A., serves as President & Chief Executive Officer of Aspira Women's Health Inc. since March 1, 2022 and serves as its Director since February 17, 2021 & serves as it's Interim CFO...

Leadership Team

NamePositionTenureCompensationOwnership
Nicole Sandford
CEO, Interim CFO & Director2.6yrsUS$1.04m0.52%
$ 64.1k
Sandra Milligan
Presidentless than a yearno datano data
John Kallassy
Interim Chief Financial Officerless than a yearno datano data
Michelle Snider
Senior Vice President of Commercial Strategy & Operations1.2yrsno datano data

0.8yrs

Average Tenure

Experienced Management: CUL's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Nicole Sandford
CEO, Interim CFO & Director3.7yrsUS$1.04m0.52%
$ 64.1k
Ellen Vos
Independent Director1.4yrsUS$115.58k0.33%
$ 40.4k
Daniel Chan
Member of Scientific Advisory Board18.3yrsno datano data
Jannie Herchuk
Independent Chair of the Board1.4yrsUS$118.83k0.30%
$ 37.4k
Stefanie Cavanaugh
Independent Director1.4yrsUS$113.96k0.34%
$ 42.1k
Donald Munroe
Member of Scientific Advisory Boardno dataUS$484.75kno data
Judith Wolf
Member of Scientific Advisory Boardno datano datano data
Robert Bristow
Member of Scientific Advisory Boardno datano datano data
Calaneet Balas
Member of Scientific Advisory Boardno datano datano data
Farr Nezhat
Member of Scientific Advisory Boardno datano datano data
Celeste Fralick
Independent Director2.7yrsUS$178.00k0.25%
$ 31.2k
Leo Twiggs
Chairman of Clinical Advisory Boardless than a yearno datano data

1.4yrs

Average Tenure

64yo

Average Age

Experienced Board: CUL's board of directors are not considered experienced ( 1.4 years average tenure), which suggests a new board.